<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.1/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.1/"
>

<channel>
	<wp:wxr_version>1.1</wp:wxr_version>
	
	<wp:author><wp:author_id>2</wp:author_id><wp:author_login>admin</wp:author_login><wp:author_email>nick@trialfacts.com</wp:author_email><wp:author_display_name><![CDATA[admin]]></wp:author_display_name><wp:author_first_name><![CDATA[Nick]]></wp:author_first_name><wp:author_last_name><![CDATA[Karrasch]]></wp:author_last_name></wp:author>


	<generator>http://wordpress.org/?v=3.1.3</generator>	<item>		<title>Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases</title>		<dc:creator>admin</dc:creator>		<content:encoded><![CDATA[<div class="section"><h3>Background</h3><div class="holder">
      RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain
      or fractures) caused by bone metastases and androgen deprivation therapy. It is not yet
      known whether treatment with zoledronate is effective in preventing bone-related events in
      patients who have prostate cancer and bone metastases.

      PURPOSE: This randomized phase III trial is studying how well zoledronate works in
      preventing bone-related events in patients who are receiving androgen deprivation therapy
      for prostate cancer and bone metastases.
    </div></div>]]></content:encoded>		<wp:post_id>0</wp:post_id>		<wp:comment_status>open</wp:comment_status>		<wp:ping_status>closed</wp:ping_status>		<wp:post_name>zoledronate-in-preventing-skeletal-(bone)-related-events-in-patients-who-are-receiving-androgen-deprivation-therapy-for-prostate-cancer-and-bone-metastases</wp:post_name>		<wp:status>publish</wp:status>		<wp:post_type>medical-trial</wp:post_type>		<category domain="category" nicename="alaska"><![CDATA[Alaska]]></category>		<category domain="post_tag" nicename="prostate-cancer"><![CDATA[Prostate Cancer]]></category>		<wp:postmeta>			<wp:meta_key>rcenter</wp:meta_key>			<wp:meta_value><![CDATA[Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital]]></wp:meta_value>		</wp:postmeta>		<wp:postmeta>			<wp:meta_key>location</wp:meta_key>			<wp:meta_value><![CDATA[Fairbanks,Alaska,United States]]></wp:meta_value>		</wp:postmeta>		<wp:postmeta>			<wp:meta_key>lphysician</wp:meta_key>			<wp:meta_value><![CDATA[Matthew R. Smith, MD]]></wp:meta_value>		</wp:postmeta>		<wp:postmeta>			<wp:meta_key>ethicalrb</wp:meta_key>			<wp:meta_value><![CDATA[Unspecified]]></wp:meta_value>		</wp:postmeta>		<wp:postmeta>			<wp:meta_key>participate1</wp:meta_key>			<wp:meta_value><![CDATA[Male]]></wp:meta_value>		</wp:postmeta>		<wp:postmeta>			<wp:meta_key>participate2</wp:meta_key>			<wp:meta_value><![CDATA[Age: 18 Years to N/A]]></wp:meta_value>		</wp:postmeta>		<wp:postmeta>			<wp:meta_key>participate3</wp:meta_key>			<wp:meta_value><![CDATA[
        DISEASE CHARACTERISTICS:

         <br /> -  Histologically confirmed adenocarcinoma of the prostate

         <br /> -  No small cell, neuroendocrine, or transitional cell carcinomas

         <br /> -  At least 1 bone metastasis by bone scan, MRI, CT scan, or plain radiographs

              <br /> -  Indeterminate lesions should be confirmed by a second imaging method

              <br /> -  At least 1 bone metastasis with no prior irradiation

         <br /> -  Concurrent androgen deprivation therapy required, defined as any of the following:

              <br /> -  Bilateral orchiectomy

              <br /> -  Gonadotropin-releasing hormone (GnRH) agonist with or without an antiandrogen

        PATIENT CHARACTERISTICS:

        Age

         <br /> -  18 and over

        Performance status

         <br /> -  ECOG 0-2

        Life expectancy

         <br /> -  Not specified

        Hematopoietic

         <br /> -  Not specified

        Hepatic

         <br /> -  Not specified

        Renal

         <br /> -  Creatinine clearance ≥ 30 mL/min

         <br /> -  Corrected calcium ≥ 8.0 mg/dL and < 11.6 mg/dL

        Other

         <br /> -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

         <br /> -  Concurrent standard biologic response modifiers allowed during open-label therapy
             only

        Chemotherapy

         <br /> -  Concurrent standard cytotoxic chemotherapy allowed during open-label therapy only

        Endocrine therapy

         <br /> -  See Disease Characteristics

         <br /> -  Prior neoadjuvant and/or adjuvant hormonal therapy allowed provided duration of
             therapy was no more than 6 months AND therapy was discontinued more than 6 months
             before study entry

         <br /> -  No more than 6 months since initiation of any of the following hormonal therapies:

              <br /> -  Orchiectomy

              <br /> -  GnRH agonist (e.g., leuprolide, goserelin, or triptorelin)

              <br /> -  Estrogen therapy

              <br /> -  Antiandrogens (e.g., bicalutamide, flutamide, or nilutamide)

              <br /> -  Any other therapy known to lower testosterone levels or inhibit testosterone
                  effect

         <br /> -  No intermittent androgen deprivation therapy except for patients concurrently
             enrolled on SWOG-9346

         <br /> -  Concurrent palliative corticosteroids allowed during open-label therapy only

         <br /> -  Concurrent standard hormonal agents allowed during open-label therapy only

        Radiotherapy

         <br /> -  See Disease Characteristics

         <br /> -  No prior radiopharmaceuticals

         <br /> -  At least 4 weeks since prior radiotherapy

         <br /> -  Concurrent standard radiotherapy to extraskeletal tumor sites allowed during
             open-label therapy only

        Surgery

         <br /> -  See Disease Characteristics

        Other

         <br /> -  No prior bisphosphonates

         <br /> -  No prior denosumab

         <br /> -  No other concurrent agents expected to alter osteoclast activity (e.g., denosumab,
             calcitonin, mithramycin, gallium nitrate, or any other bisphosphonate)

         <br /> -  Concurrent daily supplemental elemental calcium (500 mg) and a multivitamin
             containing cholecalciferol (Vitamin D) (400 IU) OR a combination tablet containing
             both recommended

         <br /> -  Concurrent standard marketed antineoplastic therapies allowed during open-label
             therapy only
      ]]></wp:meta_value>		</wp:postmeta>	</item></channel></rss>